The promise of precision medicine: how biomarkers are shaping the future of cholangiocarcinoma treatment
Name:
37351132.pdf
Size:
292.5Kb
Format:
PDF
Description:
Identified with Open Access button
Affiliation
Experimental Hepatology and Drug Targeting (HEVEPHARM), IBSAL, University of Salamanca, Salamanca, SpainIssue Date
2023
Metadata
Show full item recordAbstract
NoneCitation
Macias RIR, Rimassa L, Lamarca A. The promise of precision medicine: how biomarkers are shaping the future of cholangiocarcinoma treatment. Hepatobiliary Surg Nutr. 2023 Jun 1;12(3):457-61. PubMed PMID: 37351132. Pubmed Central PMCID: PMC10282684. Epub 2023/06/23. eng.Journal
Hepatobiliary Surgery and NutritionDOI
10.21037/hbsn-23-215PubMed ID
37351132Additional Links
https://dx.doi.org/10.21037/hbsn-23-215Type
OtherLanguage
enae974a485f413a2113503eed53cd6c53
10.21037/hbsn-23-215
Scopus Count
Collections
Related articles
- How to incorporate new agents into precise medicine for cholangiocarcinoma?
- Authors: Li Y, Kang J, Zhang X
- Issue date: 2024
- Precision medicine in cholangiocarcinoma.
- Authors: Pellino A, Loupakis F, Cadamuro M, Dadduzio V, Fassan M, Guido M, Cillo U, Indraccolo S, Fabris L
- Issue date: 2018
- Molecular genetics and targeted therapeutics in biliary tract carcinoma.
- Authors: Marks EI, Yee NS
- Issue date: 2016 Jan 28
- Cholangiocarcinoma: shedding light on the most promising drugs in clinical development.
- Authors: Rahnemai-Azar AA, Pawlik TM
- Issue date: 2021 Apr
- The state of therapy modalities in clinic for biliary tract cancer.
- Authors: Chen W, Hu Z, Song J, Wu Y, Zhang B, Zhang L
- Issue date: 2022 Jun 8